Skip to main
ANL
ANL logo

ANL Stock Forecast & Price Target

ANL Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adlai Nortye Ltd demonstrates a positive outlook due to its diverse and promising pipeline, particularly with candidate AN8025, which has shown preclinical data indicating enhanced T cell responses and effective modulation of antigen presenting cells, surpassing existing treatments. Furthermore, the company is well-positioned with AN9025, a pan-KRAS inhibitor, targeting a critical unmet need in addressing various KRAS mutations beyond the KRAS-G12C variant, thereby expanding its therapeutic potential in oncology. These innovative developments in cancer therapy, coupled with strong scientific backing, highlight the company's capability to advance its clinical programs and meet significant market demands.

Bears say

Adlai Nortye Ltd has faced significant setbacks with the disappointing results from its buparlisib program, leading to its discontinuation. This failure highlights broader concerns regarding the company's ability to navigate clinical trials successfully, as well as its capacity to secure necessary funding for the progression of its drug development initiatives. Additionally, the risk of dilutive capital raises poses a further challenge to the company's financial stability and overall outlook.

ANL has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adlai Nortye Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adlai Nortye Ltd (ANL) Forecast

Analysts have given ANL a Strong Buy based on their latest research and market trends.

According to 1 analysts, ANL has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adlai Nortye Ltd (ANL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.